Use of an optimized monoclonal antibody for preparing a medicinal product for the treatment of pathologies which escape the immune response

摘要

Use of an optimized chimeric humanized or human monoclonal antibody (MAb) to produce a composition for treating disease in which: (a) the number of antigen sites (antigenic density) is low or the antigens are poorly accessible to antibodies; or (b) the number of effector cells (EC) activated or recruited is low. Use of an optimized chimeric humanized or human monoclonal antibody (MAb) to produce a composition for treating disease in which: (a) the number of antigen sites (antigenic density) is low or the antigens are poorly accessible to antibodies; or (b) the number of effector cells (EC) activated or recruited is low. MAb has a glycan structure generally of the 'two-antennae' type, with short chains, low level of silylation of mannose and GlcNAc at the non-intercalated terminal points of attachment, low level of fucosylation and non-zero level of intermediate GlcNAc.